Results 31 to 40 of about 12,502 (244)

Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data

Critical Care, 2023
Background Retrospective cohorts have suggested that levosimendan may facilitate the weaning of veno-arterial extracorporeal membrane oxygenation (VA-ECMO).
J. Massol, Noémie Simon-Tillaux, J. Tohme, Geoffroy Hariri, P. Dureau, B. Duceau, Lisa Belin, D. Hajage, Y. de Rycke, Ahmed Charfeddine, G. Lebreton, A. Combes, Adrien Bouglé   +12 more
semanticscholar   +1 more source

Single-center experience with levosimendan in children undergoing cardiac surgery and in children with decompensated heart failure

BMC Anesthesiology, 2011
Background Levosimendan has pharmacologic and hemodynamic advantages over conventional intravenous inotropic agents. It has been used mainly as a rescue drug in the pediatric intensive care unit or in the operating room.
Suominen Pertti K
doaj   +1 more source

Evaluation of levosimendan as treatment option in a large case-series of preterm infants with cardiac dysfunction and pulmonary hypertension

European Journal of Pediatrics, 2023
Levosimendan as a calcium-sensitizer is a promising innovative therapeutical option for the treatment of severe cardiac dysfunction (CD) and pulmonary hypertension (PH) in preterm infants, but no data are available analyzing levosimendan in cohorts of ...
Lukas Schroeder, Stanley Holcher, J. Leyens, A. Geipel, B. Strizek, T. Dresbach, Andreas Mueller, F. Kipfmueller   +7 more
semanticscholar   +1 more source

The Impact of Levosimendan on Survival and Weaning from ECMO after Extracorporeal Cardiopulmonary Resuscitation.

Artificial Organs, 2023
OBJECTIVES Extracorporeal cardiopulmonary resuscitation (eCPR) is increasingly used due to its beneficial outcomes and results compared to conventional CPR. After cardiac arrest, the overall ejection fraction is severely impaired; thus, weaning from ECMO
C. Gaisendrees, G. Schlachtenberger, Stephen Gefer, Ihor Karsivskyi, I. Djordjevic, A. Sabashnikov, Marinos Kosmopoulos, Déborah Jaeger, M. Luehr, E. Kuhn, A. Deppe, T. Wahlers   +11 more
semanticscholar   +1 more source

Levosimendan for patients with severely reduced left ventricular systolic function and/or low cardiac output syndrome undergoing cardiac surgery. a systematic review and meta-analysis [PDF]

, 2017
Background: Previous studies have shown beneficial effects of levosimendan in high-risk patients undergoing cardiac surgery. Two large randomized controlled trials (RCTs), however, showed no advantages of levosimendan.
Arcadipane, Antonio, Knight, Joshua B., Lorini, Ferdinando L., Morelli, Andrea, Pastore, Federico, Sanfilippo, Filippo, Santonocito, Cristina, Scolletta, Sabino, Tritapepe, Luigi   +8 more
core   +2 more sources

Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels.

PLoS ONE, 2020
INTRODUCTION:Levosimendan is approved for acute heart failure. Within this context, pulmonary hypertension represents a frequent co-morbidity. Hence, the effects of levosimendan on segmental pulmonary vascular resistance (PVR) are relevant.
Annette Dorothea Rieg, Said Suleiman, Nina Andrea Bünting, Eva Verjans, Jan Spillner, Heike Schnöring, Sebastian Kalverkamp, Thomas Schröder, Saskia von Stillfried, Till Braunschweig, Gereon Schälte, Stefan Uhlig, Christian Martin   +12 more
doaj   +1 more source

Levosimendan inhibits disulfide tau oligomerization and ameliorates tau pathology in TauP301L-BiFC mice

Experimental and Molecular Medicine, 2023
Tau oligomers play critical roles in tau pathology and are responsible for neuronal cell death and transmitting the disease in the brain. Accordingly, preventing tau oligomerization has become an important therapeutic strategy to treat tauopathies ...
Sungsu Lim, Seulgi Shin, Y. Sung, H. Lee, Kyu Hyeon Kim, Ji Yeon Song, G. Lee, Hira Aziz, Nataliia Lukianenko, Dong Min Kang, Nicolette Boesen, Hyeanjeong Jeong, Aizhan Abdildinova, Junghee Lee, B. Yu, S. Lim, Jun‐Seok Lee, H. Ryu, A. Pae, Y. Kim   +19 more
semanticscholar   +1 more source

Treatment with levosimendan in an experimental model of early ventilator-induced diaphragmatic dysfunction

Drug Target Insights, 2023
Introduction: Mechanical ventilation (MV) is a life-saving approach in critically ill patients. However, it may affect the diaphragmatic structure and function, beyond the lungs.
Vanessa Zambelli, Emma J. Murphy, Paolo Del Vecchio, Laura Rizzi, Roberto Fumagalli, Emanuele Rezoagli, Giacomo Bellani   +6 more
doaj   +1 more source

Oral Levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial [PDF]

, 2019
Objective To evaluate the efficacy and safety of oral levosimendan in amyotrophic lateral sclerosis (ALS) patients. This phase 2, randomised, double-blind, placebo-controlled, crossover, 3-period study with 6 months open-label follow-up enrolled adults ...
Aho, Valtteri V, Al-Chalabi, Ammar, Hardiman, Orla, Kuoppamäki, Mikko, Leigh, P Nigel, Ludolph, Albert, Sarapohja, Toni, Shaw, Pamela, van den Berg, Leonard   +8 more
core   +2 more sources

The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery

Journal of Cardiovascular Development and Disease, 2023
Background: Postoperative myocardial dysfunction following cardiac surgery is a relatively common occurrence. Levosimendan, a calcium sensitizer and inotropic drug, has shown potential in improving outcomes for patients with low preoperative ejection ...
Vasileios Leivaditis, Konstantinos Grapatsas, Anastasia Papaporfyriou, Michail Galanis, Efstratios Koletsis, Nikolaos Charokopos, Erich Haussmann, Vladislav Kaplunov, Athanasios Papatriantafyllou, Manfred Dahm   +9 more
doaj   +1 more source